The Role of Metastasectomy in Urothelial Carcinoma: Where Are We in 2020?
Clin Genitourin Cancer
; 18(4): e478-e483, 2020 08.
Article
in En
| MEDLINE
| ID: mdl-32085986
Systemic therapy is the mainstay of treatment for metastatic urothelial carcinoma (UC). Responses to first-line platinum-based therapy tend to be short-lived with potential toxicity. Despite the approval of checkpoint inhibitors, the long-term prognosis for patients with metastatic UC remains dismal. Herein we report the case of a patient with a solitary pulmonary metastatic lesion of urothelial origin as the only site of metastatic disease who remained free of disease for more than 2 years without systemic therapy after metastasectomy. We review the literature discussing the role of combined surgical and medical management of oligometastatic UC. As our case illustrates, a growing body of evidence suggests a potential role for a multimodal approach in patients with oligometastatic UC.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Urologic Neoplasms
/
Metastasectomy
Type of study:
Prognostic_studies
Limits:
Humans
Language:
En
Journal:
Clin Genitourin Cancer
Journal subject:
NEOPLASIAS
/
UROLOGIA
Year:
2020
Document type:
Article
Country of publication: